Diisopropylethylamine → 2-(3-{methyl-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-amino}-propyl)-thiazole-4-carboxylic acid methyl-(R)-1,2,3,4-tetrahydro-naphthalen-1-yl-amide

HRID 470723

Reaktionsgleichung

Reaktionsgleichung von HRID 470723
[CH3:1][C:2]1[N:6]([CH2:7][C:8]([OH:10])=O)[N:5]=[C:4]([C:11]([F:14])([F:13])[F:12])[CH:3]=1.C(N(C(C)C)CC)(C)C.C[NH3+].F[P-](F)(F)(F)(F)F.N1(OC(N(C)C)=[N+](C)C)C2N=CC=CC=2N=N1.F[P-](F)(F)(F)(F)F.Cl.[CH3:58][N:59]([C@H:72]1[C:81]2[C:76](=[CH:77][CH:78]=[CH:79][CH:80]=2)[CH2:75][CH2:74][CH2:73]1)[C:60]([C:62]1[N:63]=[C:64]([CH2:67][CH2:68][CH2:69][NH:70][CH3:71])[S:65][CH:66]=1)=[O:61]>C(#N)C>[CH3:58][N:59]([C@H:72]1[C:81]2[C:76](=[CH:77][CH:78]=[CH:79][CH:80]=2)[CH2:75][CH2:74][CH2:73]1)[C:60]([C:62]1[N:63]=[C:64]([CH2:67][CH2:68][CH2:69][N:70]([CH3:71])[C:8](=[O:10])[CH2:7][N:6]2[C:2]([CH3:1])=[CH:3][C:4]([C:11]([F:14])([F:13])[F:12])=[N:5]2)[S:65][CH:66]=1)=[O:61]

Komponenten

6

Versuchsvorschrift

To a solution of (5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetic acid (0.053 g, 0.25 mmol) in acetonitrile (3 mL) was added diisopropylethylamine (0.17 mL, 1.01 mmol), followed by 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium (0.11 g, 0.3 mmol). After stirring 15 min at RT, 2-(3-methylamino-propyl)-thiazole-4-carboxylic acid methyl-(R)-1,2,3,4-tetrahydro-naphthalen-1-yl-amide hydrochloride salt (0.096 g, 0.25 mmol) was added to the reaction mixture. After stirring overnight at RT, solvent was evaporated and the resulting yellow oil was dissolved in ethylacetate (20 mL), washed with saturated aqueous sodium bicarbonate solution (30 mL), 1M HCl solution (10 mL), and brine (10 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated under reduced pressure. The crude mixture was purified by column chromatography on silica gel (ethylacetate/cyclohexane 7:3) to give 2-(3-{methyl-[2-(5-methyl-3-trifluoromethyl-pyrazol-1-yl)-acetyl]-amino}-propyl)-thiazole-4-carboxylic acid methyl-(R)-1,2,3,4-tetrahydro-naphthalen-1-yl-amide (Compound No. 1.d.55, 83 mg, 61%). 1H-NMR (400 MHz, CDCl3): δ=7.75-7.80 (s, 1H (conformers)), 7.31-7.29 (m, 1H), 7.20-7.06 (m, 3H), 6.35-6.25 (s, 1H (conformers)), 6.05-5.55 (m, 1H (conformers)), 5.05-4.75 (s, 2H (conformers)), 3.55-3.46 (m, 2H), 3.10-2.90 (s, 3H (conformers)), 3.08-3.05 (m, 1H), 2.90-2.75 (s, 3H (conformers)+m, 3H), 2.30-2.20 (s, 3H (conformers)), 2.15-1.61 (m, 6H). MS: m/z=534 (M+1).

Aufarbeitung

  1. stirringAfter stirring overnight at RT
  2. customsolvent was evaporated
  3. dissolutionthe resulting yellow oil was dissolved in ethylacetate (20 mL)
  4. washwashed with saturated aqueous sodium bicarbonate solution (30 mL), 1M HCl solution (10 mL), and brine (10 mL)
  5. dry with materialThe organic layer was dried over sodium sulfate
  6. filtrationfiltered
  7. customevaporated under reduced pressure
  8. customThe crude mixture was purified by column chromatography on silica gel (ethylacetate/cyclohexane 7:3)

Quellen und Nachweise

ORD-Eintrag
ord-bfea0fdff62e42aabeabf8750de5a5cb
Quelldatensatz
uspto-grants-2014_01
Patentnummer
US08629286B2

Verknüpfte Notizen

Wird geladen…